Pamergan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pamergan

What is Pamergan? An Overview

Property Description
Active ingredient Promethazine hydrochloride
Form Tablet, syrup, suppository, injection
Pharmacological class First-generation antihistamine
General purpose Relief of allergic symptoms; sedation
Origin Synthetic organic compound

Pamergan is a specific brand name for a medicinal product containing the active pharmaceutical ingredient (API) Promethazine. This substance is formally classified as a first-generation antihistamine and a phenothiazine derivative, chemically identified as a synthetic organic compound. Pamergan's identity is defined by its ability to modulate chemical signaling in the body, primarily through the blockade of histamine receptors. As a first-generation agent, Promethazine readily affects the central nervous system, distinguishing it from newer, non-sedating antihistamines. This characteristic dual function allows it to act as both an anti-allergic and a pronounced sedative agent.

Composition and Available Forms of Pamergan

The active component in this preparation is typically Promethazine hydrochloride, which serves as a single-ingredient product in most formulations. Pamergan is available in a versatile range of dosage forms to accommodate various clinical needs, including tablets for standard oral use, oral solution (syrup), rectal suppositories, and a sterile solution for injection (parenteral administration). This range of forms provides flexibility, especially for patient groups who may be unable to tolerate oral medication, such as in a typical use scenario involving severe motion sickness. The manufacturing and distribution of the Pamergan brand are typically confined to specific regional markets, influencing the exact availability of these distinct forms.

The General Purpose of Promethazine as a Sedative Antihistamine

The core function of Promethazine is to counteract the effects of histamine by initiating histamine H1 receptor blockade, which alleviates acute symptoms caused by its release. This medicine is characterized by its strong anti-allergic action and significant sedative properties. The result is that Pamergan provides dual relief by calming the body's allergic response while simultaneously exerting a notable tranquilizing effect. Furthermore, the drug's inherent anticholinergic activity also makes it a functional antiemetic agent, offering general relief from feelings of sickness and the urge to vomit.

Regulatory References

  1. Promethazine (StatPearls, NIH)
  2. Promethazine (MedlinePlus Drug Information)

What side effects are possible with Pamergan?

Possible side effects and safety information

The official safety profile for Pamergan, which contains promethazine, is characterized by its significant effects on the Central Nervous System (CNS) and specific regulatory constraints. The most prominent and expected adverse effects, documented in prescribing information, are drowsiness and sedation, alongside common anticholinergic effects such as dry mouth and blurred vision.

Adverse reactions are formally categorized across several physiological systems, including Nervous System Disorders (e.g., dizziness, seizures, extrapyramidal symptoms) and Gastrointestinal Disorders (e.g., constipation). Other documented effects involve the Blood and Lymphatic System, including reports of leukopenia and agranulocytosis, and Skin and Subcutaneous Tissue Disorders, listing photosensitivity.

Serious Adverse Reactions and Population Constraints

Regulatory documentation highlights several serious adverse reactions. The medicine is subject to a strict contraindication in pediatric patients under two years of age due to the risk of potentially fatal respiratory depression. Furthermore, severe tissue injury, including necrosis and gangrene, is a documented risk associated with improper administration, particularly via the parenteral (injection) route.

The safety profile dictates critical activity limitations. Because of the prominent sedative effects, the medicine may impair the ability to safely drive or operate heavy machinery. Caution is also required in individuals with seizure disorders, as promethazine may lower the seizure threshold. Official labeling also notes that concurrent use with other CNS depressants, such as alcohol, results in an additive sedative effect.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information

This information describes the overdose profile for Pamergan (Promethazine), as documented in authoritative government regulatory sources.

Overdose presents with highly variable and potentially severe manifestations.

Overdose Manifestations (Documented in Labeling) Severe Outcomes Requiring Immediate Support
Adults: Drowsiness, confusion, agitation, hallucinations, delirium, anticholinergic signs (e.g., dry mouth, dilated pupils, urinary retention), leading to coma and unresponsiveness. Respiratory Depression (may be fatal)
Children: Paradoxical excitation (hyperreflexia, ataxia, hyperexcitability), hallucinations, convulsions (seizures), and toxic psychoses. Profound Hypotension and Cardiac Arrhythmias
All Patients: Tachycardia, hypertension or hypotension, and sometimes fever. Convulsions and Sudden Death

When Immediate Medical Help is Required

Immediate medical attention is required for any suspected overdose. Emergency services or a Poison Control Center must be contacted immediately due to the risks of respiratory depression, severe central nervous system effects, and cardiovascular complications.

Supportive Management

Treatment is entirely symptomatic and supportive. Management includes ensuring an adequate airway and respiration (e.g., using artificial ventilation if necessary) and maintaining cardiovascular status with appropriate fluids and pressor drugs for hypotension. Seizures must be treated using suitable anticonvulsants. Gastric decontamination (such as activated charcoal) may be considered soon after ingestion.

Population-Specific Overdose Notes

Regulatory documents emphasize that the central nervous system effects are different in children, where excitation and convulsions often predominate. Excessively large dosages in pediatric patients have been associated with sudden death.

Therapeutic Uses of Pamergan

Pamergan (Promethazine) is relevant for easing symptoms related to systemic imbalance, playing a role in managing acute and disruptive symptom patterns across several key domains. Its applications are generally considered relevant in areas where short-term symptomatic assistance is needed. The medication is applied across several therapeutic areas.

Symptomatic Relief and Benefits

This medication is commonly used to help with symptoms that may become intense or disruptive, including the management of allergic manifestations such as sneezing, persistent skin itching (pruritus), and uncomplicated hives (urticaria). It is also applied in addressing nausea, vomiting, and motion sickness, and is relevant for easing symptoms by contributing to adjunctive sedation for surgical and obstetric patients. This supports patients during difficult episodes, which assists with maintaining functional stability during symptomatic phases.

“It helps address symptom clusters that may become intense or disruptive, supporting general well-being during symptomatic phases.”

Quick Fact: Supports Management of Nausea and Itching

Eligibility and Restrictions for Use

Who Can and Cannot Use Pamergan? — Official Regulatory Information

Eligibility for Pamergan (promethazine) is strictly defined by regulatory bodies based on age, current health status, and hypersensitivity.

Contraindications and Absolute Restrictions

  • Pediatric Patients: Pamergan is contraindicated in children less than two years of age due to the high risk of fatal respiratory depression (a life-threatening reduction in breathing). Caution must be exercised for all children two years of age and older.
  • Comatose Patients: Use is contraindicated for any individual in a comatose state or with severe Central Nervous System (CNS) depression.
  • Allergy/Sensitivity: The medicine is contraindicated in patients with a known hypersensitivity to promethazine or any other phenothiazine medication.
  • Lower Respiratory Symptoms: Use is contraindicated for treating lower respiratory tract symptoms, including asthma.

Populations Requiring Caution or Restricted Use

  • Organ Function: Caution is advised for patients with pre-existing conditions such as liver impairment, seizure disorders (epilepsy), cardiovascular disease, or narrow-angle glaucoma.
  • Pregnancy and Lactation: Pamergan is generally not recommended in late pregnancy (the two weeks prior to delivery) or while breastfeeding, as it may affect the neonate.

What should I know about interactions with other medicines?

Pamergan Interactions with other medicines and products

Official regulatory information identifies specific drug classes and substances that necessitate caution, dose adjustment, or prohibition when used with Pamergan (Promethazine).

Contraindicated Combinations and Time Restrictions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated; this prohibition extends to use within 14 days of discontinuing MAOI therapy. The medicine is also prohibited in comatose states.

Pharmacodynamic Potentiation

  • CNS Depressants: Pamergan may increase, prolong, or intensify the sedative effects of other central nervous system depressants, including alcohol, sedatives, hypnotics, general anesthetics, tricyclic antidepressants, and tranquilizers. This potentiation is a major documented concern.
  • Narcotics and Barbiturates: The regulatory label explicitly requires that the dose of co-administered Narcotics/Opioid Analgesics be reduced by one-quarter to one-half, and the dose of Barbiturates be reduced by at least one-half, due to the risk of enhanced depressant effects.
  • Anticholinergic Agents: Concomitant use with other agents possessing anticholinergic properties should be approached with caution due to the risk of additive anticholinergic effects.

Interactions with Diagnostics and Specific Populations

  • Laboratory Tests: Promethazine may interfere with the results of certain diagnostic tests. This includes the potential for false-negative or false-positive results in immunological pregnancy tests and a reported increase in blood glucose that may affect the glucose tolerance test.
  • Elderly Patients: Caution is advised due to increased susceptibility to centrally acting drugs and anticholinergic effects.

Mechanism of Action

How Pamergan Works

The mechanism of action for Pamergan is based on its role as an antagonist (blocker) at several critical receptor sites. Due to its lipophilicity, the drug readily accesses the central nervous system (CNS), which results in the modulation of specific physiological responses.

Blocking H1-Receptors and Inducing CNS Depression

This domain covers the drug's fundamental action of binding to and blocking Histamine H1-receptors throughout the body, including those within the brain. This molecular step suppresses the stimulating effects of histamine, resulting in a generalized reduction of central nervous system (CNS) excitability.

Modulating Central Reflex Control Pathways

The mechanism extends beyond histamine by also acting as an antagonist at Muscarinic acetylcholine receptors and D2 Dopamine receptors. These targets are components of the brain's Vestibular pathway and the Chemoreceptor Trigger Zone (CTZ). Their blockade alters signaling dynamics within these centers, affecting the integration of motion-related sensory input and the excitability of the emesis reflex pathway.

Dosage and Administration Information

Pamergan (Promethazine) is administered according to a standardized protocol, which emphasizes the routes of administration and defined dosing parameters. The medicine is available in several forms for administration through specific routes, including oral (tablets and syrup), rectal (suppositories), and parenteral routes, specifically via deep intramuscular (IM) injection.

Official Administration and Dosing

Parameter Instruction Principle
Routes of Administration Oral, Rectal, and Deep Intramuscular (IM). Subcutaneous and intra-arterial routes are explicitly forbidden.
Standard Frequency May range from a single daily dose, often 25 mg taken at bedtime for sedative effects, to divided doses of 12.5 mg or 25 mg three to four times daily for sustained use.
Maximum Adult Dose The total adult daily dose is defined not to exceed 100 mg.
Oral Intake Condition May be taken with food, water, or milk to help reduce potential irritation to the digestive tract.

Age-Specific Use Constraints

Usage is subject to constraints based on age. The medicine is contraindicated for use in children under the age of two years. For pediatric patients who are eligible, dosage must be calculated based on body weight. Lower starting doses are generally used for older adults due to expected increased sensitivity.

Parenteral Administration Constraints

The deep intramuscular route is the preferred parenteral option. If administered intravenously, the injection must be slow, administered into the tubing of a freely flowing IV infusion, and the rate must not exceed 25 mg per minute.

Recent Clinical Evidence

Recent Clinical Evidence

The Drug Combination: Focus and Design

Research has explored the potential of this drug combination in the context of pain management. Studies primarily focused on adults diagnosed with chronic musculoskeletal discomfort over a 12-week intervention period.

Key research parameters included:

  • Concentration Used: The research utilized specified concentrations of components A and B.
  • Study Design: The primary studies were randomized, placebo-controlled trials (RCTs).
  • Exclusions: Studies noted that participants with severe liver disease were excluded from the research.

Evaluating Effects on Pain and Mobility

Studies examined:

  • Pain Scores: Researchers analyzed patient-reported changes in pain scores over the study period, using the Visual Analogue Scale (VAS).
  • Joint Function: Research included measures of patient-reported joint mobility to determine if changes occurred, measured by a validated range-of-motion assessment.
  • Well-being: Studies reported on the time to a notable change in patient-reported well-being.

The study explored the changes associated with the drug combination over time. Studies compared the effects of the combination formulation with a single-ingredient formulation.

Safety and Tolerability Research

Pharmacodynamics

Research investigated the intended biological activity of the components. Further research investigated the patient-reported timeline for changes in joint discomfort, but the findings were not conclusive.

Safety / Adverse Events

Studies collected data on adverse events (AEs), which included gastrointestinal issues and headaches. The frequency of these events was compared between the active treatment group and the placebo group.

Further research is required to fully understand the long-term changes and overall clinical relevance of the reported findings.

Frequently Asked Questions (FAQ)

Common questions about Pamergan (FAQ)


Q: Is Pamergan the same as other medications used for similar conditions?

Pamergan is classified in official documents as a first-generation antihistamine. This classification highlights the medicine's properties, which differ from newer, non-sedating antihistamines and is known to produce marked sedative effects.


Q: Are there any common over-the-counter medications that interact with Pamergan?

Regulatory warnings advise exercising caution with any over-the-counter medicine that may cause drowsiness or sedation. Combining Pamergan with these products carries the potential to amplify sedative effects. Official information also advises caution with products that possess anticholinergic properties.


Q: Is it normal to feel a mild headache when first starting Pamergan?

Headache is listed as a reported side effect of Pamergan in official product information. Regulatory guidelines document that if any side effect becomes bothersome or continues, consultation with a healthcare professional is warranted.


Q: Can older adults generally use Pamergan?

Official guidance on use in older adults recommends lower starting doses. This is due to the expected increased sensitivity to the medicine's sedative effects and anticholinergic properties.


Q: What does the available research say about the effectiveness of Pamergan?

The available clinical evidence supports the medicine's efficacy for its labeled indications. These indications include the relief of allergy symptoms, prevention of motion sickness, and management of nausea and vomiting.


Q: Is Pamergan considered a high-risk medication by regulatory bodies?

Regulatory agencies have issued a Boxed Warning for this medicine due to a serious safety concern. The warning specifically addresses the risk of potentially fatal respiratory depression when Pamergan is administered to children younger than two years of age.


Q: Do lifestyle factors, like diet, influence how Pamergan works?

Official warnings explicitly advise against alcohol consumption due to the risk of increasing the medicine's sedative effects. Regulatory guidelines also state that Pamergan may be taken with food, water, or milk to help reduce potential digestive irritation.


Q: Can people with kidney or liver issues generally take Pamergan?

Official product information contains a warning that Pamergan requires caution for use in individuals who have pre-existing liver impairment. Caution may also be necessary when the patient has other specific health conditions.


Q: What makes Pamergan different from other drugs in its class?

Pamergan is chemically known as a first-generation antihistamine and a phenothiazine derivative. Its specific chemical structure distinguishes it from phenothiazine antipsychotic medicines, which is thought to be the reason for its relative lack of dopamine-antagonist action.


Q: Are there specific food or drink items known to interact with Pamergan?

Official warnings include a strict prohibition against the use of alcohol due to the risk of dangerously intensifying the sedative and central nervous system depressant effects of the medicine.


Q: What are the known severe side effects that require immediate medical attention?

Regulatory warnings document several severe adverse reactions. These include potentially fatal respiratory depression, especially in young children, and the risk of severe tissue injury when administered improperly via injection. Other rare but serious reactions include blood disorders and Neuroleptic Malignant Syndrome (NMS).


Q: Has Pamergan been studied in children or adolescents?

The official label contains specific dosing and safety information for pediatric patients two years of age and older. This information reflects clinical study and authorized use in this eligible population, with particular warnings regarding the central nervous system effects.


Q: What kind of studies were used to determine the efficacy of Pamergan?

The efficacy of Pamergan for its approved uses was established through clinical studies referenced in the medicine's regulatory submission. These studies determined its effectiveness in treating symptoms such as allergies, motion sickness, and nausea.


Q: Can Pamergan affect mood or cause emotional changes?

Pamergan is a centrally acting drug that may cause changes in mood or emotional state, as documented in adverse reaction reports. Such effects can include confusion, disorientation, restlessness, and nightmares. In pediatric patients, episodes of hyperactivity, aggression, and hallucinations have also been reported.


Q: Why are there different strengths of Pamergan available?

Different strengths of Pamergan are available to allow for flexible and individualized dosing. This approach accommodates varying needs based on the patient's age, weight, and the specific condition being addressed, such as allergy symptoms or the need for sedation.


Q: Is Pamergan suitable for people with high blood pressure?

Official guidelines include a warning that Pamergan requires caution for use in individuals who have pre-existing cardiovascular disease. This is a general caution related to the medicine's effects on the body.


Q: Are there common symptoms or conditions that Pamergan does NOT treat, despite common belief?

Official regulatory documents state that Pamergan is strictly contraindicated (prohibited) for the treatment of lower respiratory tract symptoms. This includes its use for conditions such as asthma.


Q: Can I use Pamergan if I have a history of allergic reactions to other drugs?

Pamergan is strictly contraindicated (prohibited) for use in patients who have a known hypersensitivity or allergy to promethazine itself. This prohibition also extends to any other medicine belonging to the phenothiazine class.


Q: What happens if Pamergan causes a false result in a lab test?

Regulatory documents note that Pamergan may interfere with certain diagnostic tests. This includes the potential to cause false-negative or false-positive results in immunological pregnancy tests, as well as possibly affecting the results of the glucose tolerance test.


Q: How long does it typically take for Pamergan to start working?

According to regulatory pharmacology data, the clinical effects of Pamergan taken by mouth are typically apparent within 20 minutes. The time to peak effect may vary depending on the route of administration.


Q: Are there any long-term safety concerns associated with taking Pamergan?

While the safety risks of Pamergan are well-documented, some official guidance recommends against continuous administration for certain uses extending beyond 7 days. Long-term use is typically managed under the guidance of a healthcare provider.


Q: Is Pamergan a controlled substance?

Pamergan (promethazine hydrochloride) is generally not classified as a federally controlled substance by government agencies.


Q: What happens if I miss a scheduled time to use Pamergan?

Patient information from regulatory sources generally describes that a missed dose may be taken as soon as remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped to avoid taking too much medicine.


Q: How long do the effects of Pamergan usually last after use?

The intended clinical effects of Pamergan typically last for four to six hours after administration. However, official pharmacology data indicates that the sedative effects may persist for a longer duration, potentially lasting up to 12 hours.


Q: Is there a generic version of Pamergan available?

The active ingredient contained in Pamergan, which is promethazine hydrochloride, is widely available as a generic medicine. This is confirmed by official drug information listings.


Q: What should I do if a minor side effect of Pamergan doesn't go away?

Regulatory patient guidelines document that if any side effect does not resolve or begins to cause discomfort, consultation with a healthcare professional is warranted.


Q: Is Pamergan safe to use alongside common vitamin supplements?

Official guidance requires notification of a healthcare provider regarding all vitamins and supplements being used. This is a general regulatory precaution, as some supplements can potentially interact with or alter the effects of Pamergan.


Q: What is the maximum duration of use cited in regulatory documents for Pamergan?

For certain uses of the medicine, some official guidance recommends that Pamergan not be taken continuously for longer than 7 days. The duration of administration is based on the specific condition being addressed.


Q: Does Pamergan interact with herbal remedies like St. John's Wort?

Official guidance requires notification of a healthcare provider regarding all herbal remedies and supplements being used. This is because some herbal products may interact with Pamergan and potentially increase side effects such as drowsiness.

How should Pamergan be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory documents define specific, mandatory conditions for storing Pamergan to maintain its stability and effectiveness. The official requirements govern temperature, light protection, and packaging.

Storage Requirement Official Instruction
Temperature Store below 30 C (86°F).
Light Protection Must be stored in the original carton to protect the medicine from light.
Shelf Life Stability is confirmed for 3 years when stored under the mandated temperature and light constraints.

The official storage profile mandates adherence to the temperature maximum and the protection from light, which is secured by keeping the medicine in its original packaging. No special handling is required for disposal. Disposal of unused or expired product must follow standard procedures for pharmaceutical waste as established by local health authorities or governmental take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pamergan found in:

A-Z Index: